- Home
- ALT vs YMAB Comparison
ALT vs YMAB Comparison
Compare ALT & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALT
- YMAB
- Stock Information
- Founded
- ALT 1997
- YMAB 2015
- Country
- ALT United States
- YMAB United States
- Employees
- ALT N/A
- YMAB N/A
- Industry
- ALT Biotechnology: Pharmaceutical Preparations
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- ALT Health Care
- YMAB Health Care
- Exchange
- ALT Nasdaq
- YMAB Nasdaq
- Market Cap
- ALT 457.0M
- YMAB 482.4M
- IPO Year
- ALT N/A
- YMAB 2018
- Fundamental
- Price
- ALT $8.25
- YMAB $8.28
- Analyst Decision
- ALT Buy
- YMAB Strong Buy
- Analyst Count
- ALT 7
- YMAB 10
- Target Price
- ALT $20.00
- YMAB $21.00
- AVG Volume (30 Days)
- ALT 3.4M
- YMAB 303.4K
- Earning Date
- ALT 11-12-2024
- YMAB 11-08-2024
- Dividend Yield
- ALT N/A
- YMAB N/A
- EPS Growth
- ALT N/A
- YMAB N/A
- EPS
- ALT N/A
- YMAB N/A
- Revenue
- ALT $52,000.00
- YMAB $84,553,000.00
- Revenue This Year
- ALT N/A
- YMAB $6.46
- Revenue Next Year
- ALT N/A
- YMAB $20.68
- P/E Ratio
- ALT N/A
- YMAB N/A
- Revenue Growth
- ALT N/A
- YMAB N/A
- 52 Week Low
- ALT $5.28
- YMAB $6.29
- 52 Week High
- ALT $14.84
- YMAB $20.90
- Technical
- Relative Strength Index (RSI)
- ALT 48.05
- YMAB 25.63
- Support Level
- ALT $7.71
- YMAB $9.31
- Resistance Level
- ALT $9.59
- YMAB $11.10
- Average True Range (ATR)
- ALT 0.81
- YMAB 0.72
- MACD
- ALT -0.17
- YMAB -0.09
- Stochastic Oscillator
- ALT 17.17
- YMAB 7.35
About ALT Altimmune Inc.
Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.